Recognition of facial expression of emotions in Parkinson’s disease: a theoretical review

Introducción. La expresión facial emocional constituye una guía básica en la interacción social y, por ello, las alteraciones en su expresión o reconocimiento suponen una importante limitación para la comunicación. Objetivo. Examinar las capacidades de reconocimiento de expresiones faciales y su posible deterioro en la enfermedad de Parkinson. Desarrollo. En primer lugar, se revisan las investigaciones sobre este tema y que no han encontrado resultados totalmente afines. En segundo lugar, se analizan los factores que pueden explicar estas divergencias y, en particular, como tercer objetivo, se valora la relación entre los problemas en el reconocimiento emocional y el deterioro cognitivo asociado a la enfermedad. Por último, se proponen estrategias alternativas para el desarrollo de estudios que contribuyan a clarificar el estado de estas habilidades en la enfermedad de Parkinson. Conclusiones. La mayoría de los estudios indica deficiencias en el reconocimiento de expresiones, sobre todo en las de contenido emocional negativo. No obstante, es posible que dichas alteraciones estén relacionadas con las que también aparecen en otros procesos perceptivos y ejecutivos propios de la enfermedad. Para avanzar en esta cuestión, consideramos necesario diseñar estudios sobre reconocimiento emocional que impliquen diferencialmente a los procesos cognitivos mencionados o que contrasten la ejecución de los individuos con estímulos no emocionales y con expresiones faciales. Además de incrementar nuestro conocimiento sobre las consecuencias funcionales del deterioro cerebral característico de la enfermedad, estos estudios pueden indicarnos si debe prestarse atención adicional a su rehabilitación dentro de los programas que se aplicanEmotional facial expression is a basic guide during social interaction and, therefore, alterations in their expression or recognition are important limitations for communication. Aim. To examine facial expression recognition abilities and their possible impairment in Parkinson’s disease. Development. First, we review the studies on this topic which have not found entirely similar results. Second, we analyze the factors that may explain these discrepancies and, in particular, as third objective, we consider the relationship between emotional recognition problems and cognitive impairment associated with the disease. Finally, we propose alternatives strategies for the development of studies that could clarify the state of these abilities in Parkinson’s disease. Conclusions. Most studies suggest deficits in facial expression recognition, especially in those with negative emotional content. However, it is possible that these alterations are related to those that also appear in the course of the disease in other perceptual and executive processes. To advance in this issue, we consider necessary to design emotional recognition studies implicating differentially the executive or visuospatial processes, and/or contrasting cognitive abilities with facial expressions and non emotional stimuli. The precision of the status of these abilities, as well as increase our knowledge of the functional consequences of the characteristic brain damage in the disease, may indicate if we should pay special attention in their rehabilitation inside the programs implementedProyecto ref. PSI2009-09067, financiado por el Ministerio de Ciencia e Innovación

Aplicación de los clorofluorocarbonos y el hexafluoruro de azufre como trazadores hidrogeológicos en los acuíferos carbonatados del Parque Natural del Barranco del Río Dulce (Guadalajara)

Based on information from boreholes and springs of the aquifers associated with the Jurassic and Cretaceous carbonate materials near the Natural Park of the Barranco del Río Dulce (PNBRD) a conceptual groundwater flow model has been established whose dynamics was validated with the interpretation of the contents of CFC and SF6, never before used in Spain for these purposes. At all points there is a fraction of pre-1950 water that is greater in the recharge areas of the Jurassic units, where the interpretation of the data via the exponential model reflects ages up to 100 years. The interpretation of the contents of CFCs from binary mixture model reflects ages greater than 17 years for the young fraction that may correspond with water that flow through the spaces of intermediate size between the rock matrix and karst conduits. Although not belonging to the same aquifer unit, the points with the highest proportion of water “post-1950” are located in the river valleys of the Cretaceous units. The results are consistent with the existence of generally poor hydraulic gradients, because of the high apparent ages obtained, the existence of multiple inlets and at least a double porosity. In the Cretaceous aquifers there are karst conduits that raise the flow of springs quickly after rainfall and whose influence is not reflected in the samples. CFCs can be useful to indicate the existence of phenomena of current urban pollution. Age values derived from SF6 concentrations are lower than those derived from CFCs, probable due to contribution of this gas from the rock invalidating its use as tracer. The future use of CFCs is compromised by the decreasing tendency of its concentration in the atmosphere, although the comparison of CFC-113 with SF6 of no geological origin, will maintain its utility.A partir de la información procedente de los puntos de agua de los acuíferos asociados a los materiales carbonatados jurásicos y cretácicos próximos al Parque Natural del Barranco del Río Dulce (PNBRD) y de su estructura geológica, se ha establecido un modelo conceptual de flujo subterráneo cuya dinámica fue validada con la interpretación de los contenidos en CFCs y SF6, nunca antes utilizados en España con estos propósitos, de algunas muestras situadas en distintas posiciones. En todos los puntos se reconoce la existencia de una fracción de agua infiltrada antes de 1950 que es mayor en las zonas de recarga de los acuíferos de edad Jurásico donde a través del modelo exponencial se llega a edades aparentes de hasta 100 años. La interpretación de los contenidos en CFCs de todas las muestras a partir del modelo de mezcla binaria, refleja edades superiores a los 17 años para la fracción joven que puede corresponder con aquella que circula por los canales de tamaño intermedio entre la matriz rocosa y los conductos kársticos mayores. Aun no perteneciendo a la misma unidad acuífera, los puntos con mayor proporción de aguas “post-1950” se sitúan en los valles fluviales de los macizos cretácicos. Los resultados son coherentes con sistemas acuíferos de escaso gradiente general, por lo elevado de las edades aparentes obtenidas, la existencia de múltiples entradas de agua y de al menos una doble porosidad, elementos establecidos en el modelo conceptual. En los acuíferos de edad Cretácico existen conductos kársticos que elevan el caudal de los manantiales de forma rápida tras las precipitaciones y cuya influencia no se refleja en las muestras estudiadas. Los CFCs pueden ser útiles para indicar la existencia de fenómenos de contaminación urbana actual. Los valores de edad derivados de las concentraciones de SF6 son inferiores a los deducidos con los CFCs por un probable aporte de este gas del sustrato invalidando su uso como trazador. El futuro del uso de los CFCs se encuentra comprometido por la tendencia decreciente de su concentración en la atmósfera, aunque la comparación del CFC-12 con el SF6, allí donde este gas no sufra incorporaciones de origen geológico, mantendrá su utilidad

Impact of non-invasive mechanical ventilation (niv) in critical patients with influenza (H1N1) PDM09

The use of non-invasive mechanical ventilation (NIV) in patients with influenza A (H1N1)pdm09 admitted to intensive care units (ICU) has been controversial

How the Emotional Content of Discourse Affects Language Comprehension

Emotion effects on cognition have often been reported. However, only few studies investigated emotional effects on subsequent language processing, and in most cases these effects were induced by non-linguistic stimuli such as films, faces, or pictures. Here, we investigated how a paragraph of positive, negative, or neutral emotional valence affects the processing of a subsequent emotionally neutral sentence, which contained either semantic, syntactic, or no violation, respectively, by means of event-related brain potentials (ERPs). Behavioral data revealed strong effects of emotion; error rates and reaction times increased significantly in sentences preceded by a positive paragraph relative to negative and neutral ones. In ERPs, the N400 to semantic violations was not affected by emotion. In the syntactic experiment, however, clear emotion effects were observed on ERPs. The left anterior negativity (LAN) to syntactic violations, which was not visible in the neutral condition, was present in the negative and positive conditions. This is interpreted as reflecting modulatory effects of prior emotions on syntactic processing, which is discussed in the light of three alternative or complementary explanations based on emotion-induced cognitive styles, working memory, and arousal models. The present effects of emotion on the LAN are especially remarkable considering that syntactic processing has often been regarded as encapsulated and autonomous

Combination antibiotic therapy for community-acquired pneumonia

Community-acquired pneumonia (CAP) is a common and potentially serious illness that is associated with morbidity and mortality. Although medical care has improved during the past decades, it is still potentially lethal. Streptococcus pneumoniae is the most frequent microorganism isolated. Treatment includes mandatory antibiotic therapy and organ support as needed. There are several antibiotic therapy regimens that include β-lactams or macrolides or fluoroquinolones alone or in combination. Combination antibiotic therapy achieves a better outcome compared with monotherapy and it should be given in the following subset of patients with CAP: outpatients with comorbidities and previous antibiotic therapy, nursing home patients with CAP, hospitalized patients with severe CAP, bacteremic pneumococcal CAP, presence of shock, and necessity of mechanical ventilation. Better outcome is associated with combination therapy that includes a macrolide for wide coverage of atypical pneumonia, polymicrobial pneumonia, or resistant Streptococcus pneumoniae. Macrolides have shown different properties other than antimicrobial activity, such as anti-inflammatory properties. Although this evidence comes from observational, most of them retrospective and nonblinded studies, the findings are consistent. Ideally, a prospective, multicenter, randomized trial should be performed to confirm these findings

Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort

Background Patients with SARS-CoV-2 infection are at higher risk for ventilator-associated pneumonia (VAP). No study has evaluated the relationship between VAP and mortality in this population, or compared this relationship between SARS-CoV-2 patients and other populations. The main objective of our study was to determine the relationship between VAP and mortality in SARS-CoV-2 patients. Methods Planned ancillary analysis of a multicenter retrospective European cohort. VAP was diagnosed using clinical, radiological and quantitative microbiological criteria. Univariable and multivariable marginal Cox's regression models, with cause-specific hazard for duration of mechanical ventilation and ICU stay, were used to compare outcomes between study groups. Extubation, and ICU discharge alive were considered as events of interest, and mortality as competing event. Findings Of 1576 included patients, 568 were SARS-CoV-2 pneumonia, 482 influenza pneumonia, and 526 no evidence of viral infection at ICU admission. VAP was associated with significantly higher risk for 28-day mortality in SARS-CoV-2 group (adjusted HR 1.65 (95% CI 1.11-2.46), p = 0.013), but not in influenza (1.74 (0.99-3.06), p = 0.052), or no viral infection groups (1.13 (0.68-1.86), p = 0.63). VAP was associated with significantly longer duration of mechanical ventilation in the SARS-CoV-2 group, but not in the influenza or no viral infection groups. VAP was associated with significantly longer duration of ICU stay in the 3 study groups. No significant difference was found in heterogeneity of outcomes related to VAP between the 3 groups, suggesting that the impact of VAP on mortality was not different between study groups. Interpretation VAP was associated with significantly increased 28-day mortality rate in SARS-CoV-2 patients. However, SARS-CoV-2 pneumonia, as compared to influenza pneumonia or no viral infection, did not significantly modify the relationship between VAP and 28-day mortality

Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: study protocol for the SAFO trial

Introduction: Methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia is a frequent condition, with high mortality rates. There is a growing interest in identifying new therapeutic regimens able to reduce therapeutic failure and mortality observed with the standard of care of beta-lactam monotherapy. In vitro and small-scale studies have found synergy between cloxacillin and fosfomycin against S. aureus. Our aim is to test the hypothesis that cloxacillin plus fosfomycin achieves higher treatment success than cloxacillin alone in patients with MSSA bacteraemia. Methods: We will perform a superiority, randomised, open-label, phase IV-III, two-armed parallel group (1:1) clinical trial at 20 Spanish tertiary hospitals. Adults (≥18 years) with isolation of MSSA from at least one blood culture ≤72 hours before inclusion with evidence of infection, will be randomly allocated to receive either cloxacillin 2 g/4-hour intravenous plus fosfomycin 3 g/6-hour intravenous or cloxacillin 2 g/4-hour intravenous alone for 7 days. After the first week, sequential treatment and total duration of antibiotic therapy will be determined according to clinical criteria by the attending physician. Primary endpoints: (1) Treatment success at day 7, a composite endpoint comprising all the following criteria: patient alive, stable or with improved quick-Sequential Organ Failure Assessment score, afebrile and with negative blood cultures for MSSA at day 7. (2) Treatment success at test of cure (TOC) visit: patient alive and no isolation of MSSA in blood culture or at another sterile site from day 8 until TOC (12 weeks after randomisation). We assume a rate of treatment success of 74% in the cloxacillin group. Accepting alpha risk of 0.05 and beta risk of 0.2 in a two-sided test, 183 subjects will be required in each of the control and experimental groups to obtain statistically significant difference of 12% (considered clinically significant). Ethics and dissemination: Ethical approval has been obtained from the Ethics Committee of Bellvitge University Hospital (AC069/18) and from the Spanish Medicines and Healthcare Product Regulatory Agency (AEMPS, AC069/18), and is valid for all participating centres under existing Spanish legislation. The results will be presented at international meetings and will be made available to patients and funders

Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project)

REIPI/INCREMENT-SOT Group.[Background] Whether active therapy with β-lactam/β-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant recipients (KTRs) remains unclear.[Methods] We retrospectively evaluated 306 KTR admitted to 30 centers from January 2014 to October 2016. Therapeutic failure (lack of cure or clinical improvement and/or death from any cause) at days 7 and 30 from ESBL-E BSI onset was the primary and secondary study outcomes, respectively.[Results] Therapeutic failure at days 7 and 30 occurred in 8.2% (25/306) and 13.4% (41/306) of patients. Hospital-acquired BSI (adjusted OR [aOR]: 4.10; 95% confidence interval [CI]: 1.50-11.20) and Pitt score (aOR: 1.47; 95% CI: 1.21-1.77) were independently associated with therapeutic failure at day 7. Age-adjusted Charlson Index (aOR: 1.25; 95% CI: 1.05-1.48), Pitt score (aOR: 1.72; 95% CI: 1.35-2.17), and lymphocyte count ≤500 cells/μL at presentation (aOR: 3.16; 95% CI: 1.42-7.06) predicted therapeutic failure at day 30. Carbapenem monotherapy (68.6%, primarily meropenem) was the most frequent active therapy, followed by BLBLI monotherapy (10.8%, mostly piperacillin-tazobactam). Propensity score (PS)-adjusted models revealed no significant impact of the choice of active therapy (carbapenem-containing vs any other regimen, BLBLI- vs carbapenem-based monotherapy) within the first 72 hours on any of the study outcomes.[Conclusions] Our data suggest that active therapy based on BLBLI may be as effective as carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. Potential residual confounding and unpowered sample size cannot be excluded (ClinicalTrials.gov identifier: NCT02852902).This work was supported by: (1) Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III (ISCIII), Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases [RD16/0016/0001, RD16/0016/0002, REIPI RD16/0016/0008; RD16/0016/00010], co-financed by European Development Regional Fund “A way to achieve Europe”, Operative Program Intelligent Growth 2014-2020; (2) European Society of Clinical Microbiology and Infectious diseases Study Group for Infections in Compromised Hosts (ESGICH, grant to J.M.A.); (3) Sociedad Andaluza de Trasplante de Órgano Sólido (SATOT, grant to L.M.M.); (4) Research project PI16/01631 integrated into the Plan Estatal de I+D+I 2013-2016 and co-financed by the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación and the Fondo Europeo de Desarrollo Regional (FEDER); (5) M.F.R. holds a research contract “Miguel Servet” (CP 18/00073) from ISCIII, Ministerio de Ciencia, Innovación y Universidades. The work was also supported by the following European Society of Clinical Microbiology and Infectious diseases (ESCMID) study groups: Infections in Compromised Hosts (ESGICH), Bloodstream Infections and Sepsis (ESGBIS) and Antimicrobial Resistance Surveillance (ESGARS).Peer reviewe

Role of age and comorbidities in mortality of patients with infective endocarditis

Purpose: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. Methods: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015. Patients were stratified into three age groups:<65 years, 65 to 80 years, and = 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. Results: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 = 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients =80 years who underwent surgery were significantly lower compared with other age groups (14.3%, 65 years; 20.5%, 65-79 years; 31.3%, =80 years). In-hospital mortality was lower in the <65-year group (20.3%, <65 years;30.1%, 65-79 years;34.7%, =80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%, =80 years; p = 0.003).Independent predictors of mortality were age = 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI = 3 (HR:1.62; 95% CI:1.39–1.88), and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared, the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. Conclusion: There were no differences in the clinical presentation of IE between the groups. Age = 80 years, high comorbidity (measured by CCI), and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group